Second, in vivo and in vitro tumor initiation studies found PPM1Dtr to be sufficient to replace dominant-negative TP53 to enhance glioma formation in vivo and abrogate TP53-mediated G1/M cell cycle arrest and apoptosis in vitro. The gene discussed is TP53; the disease is central nervous system cancer.